Actively Recruiting
Evaluating AIC263029 for Safety and Antiviral Effects in Adults With BK Virus Infection After Kidney Transplant
Led by AiCuris Anti-infective Cures AG · Updated on 2026-10-23
24
Participants Needed
7
Research Sites
15 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying AIC263029, a drug being evaluated for safety, tolerability, and antiviral activity in adult kidney transplant recipients who have BK virus BKV in their blood. This Phase 2a randomized, double-blind, placebo-controlled trial aims to understand how the drug is processed by the body and whether it reduces BKV levels. The trial involves multiple dose levels and closely monitors safety, kidney transplant outcomes, and viral resistance. Participants receive weekly subcutaneous injections of either AIC263029 or a matching placebo for a total of five injections over a 4-week treatment period. Three dose levels 100 mg, 200 mg, and 330 mg are planned, with participants randomized in a 31 ratio to drug or placebo within each dose cohort. The study includes up to about 30 days of screening, followed by treatment and a follow-up period lasting up to approximately 24 weeks to monitor safety and antiviral effects. During the trial, participants visit the clinic for blood tests and safety assessments, including monitoring for adverse events, kidney transplant status, vital signs, and laboratory parameters. Pharmacokinetic sampling and viral DNA measurements are performed to evaluate drug levels and antiviral activity. The study also assesses viral genotyping for resistance. Total participation spans from screening through 24 weeks post-treatment to thoroughly monitor outcomes and safety.
CONDITIONS
Brief Title
A Trial to Evaluate the Safety, Tolerability and Efficacy of AIC263029 in Kidney Transplant Recipients With BKV Infection
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here